Akero Therapeutics will present findings on efruxifermin's effects on metabolic liver diseases at AASLD 2025.
Quiver AI Summary
Akero Therapeutics, Inc. announced that it will present new findings at the 76th Annual AASLD The Liver Meeting® 2025, focusing on its lead product candidate, efruxifermin (EFX), which is being studied for its safety and efficacy in patients with metabolic dysfunction-associated steatohepatitis (MASH). The presentations will include two oral sessions discussing the results of the 96-week Phase 2b SYMMETRY study, which showed improvements in fibrosis regression among patients with compensated cirrhosis, and another on the impact of EFX on portal hypertension. Additionally, a poster presentation will highlight AI-driven insights from the HARMONY study regarding changes in liver microarchitecture. Akero is dedicated to developing treatments for serious metabolic diseases and is currently conducting multiple Phase 3 studies for EFX.
Potential Positives
- Akero Therapeutics is set to present three significant studies on efruxifermin, highlighting its potential efficacy in treating compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH), which could bolster the company's reputation in the field.
- The presentations at the prestigious AASLD The Liver Meeting® 2025 may attract attention from key opinion leaders and potential investors, enhancing Akero's visibility and credibility in the market.
- Findings from the presentations may provide a stronger foundation for the ongoing Phase 3 clinical studies, which could accelerate the development timeline and bring the product closer to market approval, addressing a high unmet medical need.
Potential Negatives
- Limited data shared in the press release, lacking comprehensive results from the Phase 2b SYMMETRY and HARMONY studies, which may raise concerns about transparency and completeness for investors and stakeholders.
- Potential reliance on AI-powered digital analysis of histology data may lead to skepticism regarding the validity and robustness of the findings, as AI in medical research is still a developing field.
- No mention of any adverse events or safety concerns related to efruxifermin in the press release, which could indicate a lack of communication about challenges faced during trials.
FAQ
What is the focus of Akero Therapeutics?
Akero Therapeutics is focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH).
When will Akero present at The Liver Meeting® 2025?
Akero will present at The Liver Meeting® 2025 from November 7-11, 2025, in Washington, DC.
What will be highlighted during the presentations?
The presentations will showcase findings from the SYMMETRY and HARMONY studies on efruxifermin's efficacy in treating MASH.
Who are the presenters for the oral presentations?
The oral presentations will be given by Dr. Vlad Ratziu and Dr. Mazen Noureddin.
Where can I find more information about Akero Therapeutics?
More information about Akero Therapeutics is available on their website at akerotx.com and via their social media channels.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKRO Insider Trading Activity
$AKRO insiders have traded $AKRO stock on the open market 72 times in the past 6 months. Of those trades, 0 have been purchases and 72 have been sales.
Here’s a breakdown of recent trading of $AKRO stock by insiders over the last 6 months:
- ANDREW CHENG (President and CEO) has made 0 purchases and 16 sales selling 196,253 shares for an estimated $9,076,371.
- TIMOTHY ROLPH (Chief Scientific Officer) has made 0 purchases and 17 sales selling 97,790 shares for an estimated $4,864,058.
- CATRIONA YALE (Chief Development Officer) has made 0 purchases and 13 sales selling 44,168 shares for an estimated $2,077,968.
- JONATHAN YOUNG (Chief Operating Officer) has made 0 purchases and 10 sales selling 42,032 shares for an estimated $2,009,836.
- PATRICK LAMY (Senior VP, Commercial Strategy) has made 0 purchases and 11 sales selling 21,794 shares for an estimated $1,052,630.
- WILLIAM RICHARD WHITE (Chief Financial Officer) has made 0 purchases and 3 sales selling 5,097 shares for an estimated $269,360.
- JANE HENDERSON sold 3,000 shares for an estimated $142,371
- SCOTT A. GANGLOFF (Chief Technology Officer) sold 848 shares for an estimated $46,504
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AKRO Hedge Fund Activity
We have seen 137 institutional investors add shares of $AKRO stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVORO CAPITAL ADVISORS LLC added 3,500,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $186,760,000
- WELLINGTON MANAGEMENT GROUP LLP removed 2,526,294 shares (-42.6%) from their portfolio in Q2 2025, for an estimated $134,803,047
- POINT72 ASSET MANAGEMENT, L.P. added 2,202,589 shares (+433.3%) to their portfolio in Q2 2025, for an estimated $117,530,149
- WOODLINE PARTNERS LP added 1,986,614 shares (+413.2%) to their portfolio in Q2 2025, for an estimated $106,005,723
- RTW INVESTMENTS, LP removed 1,941,779 shares (-26.2%) from their portfolio in Q2 2025, for an estimated $103,613,327
- SG AMERICAS SECURITIES, LLC removed 1,150,442 shares (-99.5%) from their portfolio in Q2 2025, for an estimated $61,387,585
- HOLOCENE ADVISORS, LP added 1,075,642 shares (+inf%) to their portfolio in Q2 2025, for an estimated $57,396,257
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AKRO Analyst Ratings
Wall Street analysts have issued reports on $AKRO in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 08/04/2025
- B of A Securities issued a "Buy" rating on 05/27/2025
- Citigroup issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $AKRO, check out Quiver Quantitative's $AKRO forecast page.
$AKRO Price Targets
Multiple analysts have issued price targets for $AKRO recently. We have seen 4 analysts offer price targets for $AKRO in the last 6 months, with a median target of $74.0.
Here are some recent targets:
- Andrew S. Fein from HC Wainwright & Co. set a target price of $72.0 on 09/04/2025
- Ritu Baral from TD Cowen set a target price of $76.0 on 08/04/2025
- Alexandria Hammond from B of A Securities set a target price of $64.0 on 05/27/2025
- Jonathan Woo from Citigroup set a target price of $78.0 on 05/13/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76 th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH.
Details for the presentations are as follows:
Oral Presentations
Title:
Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)
Presenter:
Vlad Ratziu, M.D., Ph.D., Professor of Hepatology, Sorbonne Université and the Hôpital Pitié-Salpêtrière Medical School
Session:
Clinical Plenary #1
Date/Time:
Sunday, November 9, 2025, 12:00 PM ET
Title:
Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial
Presenter:
Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Session:
MASH Clinical Trials
Date/Time:
Sunday, November 9, 2025, 2:45 PM ET
Poster Presentation
Title:
AI-powered histology analysis of HARMONY reveals Efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH
Presenter:
Jörn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland
Session:
MASLD/MASH Therapeutics: New Agents and Approved / Available Agents
Date/Time:
Monday, November 10, 2025, from 11:30 AM-12:30 PM ET
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4c) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]
Media Contact:
Peg Rusconi
Deerfield Group
617.910.6217
[email protected]
